Healthcare utilization and expenditures associated with hyperkalemia management: a retrospective study of Medicare Advantage patients

References

• Einhorn LM, Zhan M, Hsu VD, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med. 2009;169(12):1156–1162.
   PubMed Web of Science ®Google Scholar
• Dunn JD, Benton WW, Orozco-Torrentera E, et al. The burden of hyperkalemia in patients with cardiovascular and renal disease. Am J Manag Care. 2015;21(15 Suppl 1):S307–S315.
   PubMed Web of Science ®Google Scholar
• Epstein M, Lifschitz MD. The unappreciated role of extrarenal and gut sensors in modulating renal potassium handling: implications for diagnosis of dyskalemias and interpreting clinical trials. Kidney Int Rep. 2016;1(1):43–56.
   PubMed Web of Science ®Google Scholar
• Palmer BF. Regulation of potassium homeostasis. Clin J Am Soc Nephrol. 2015;10(6):1050–1060.
   PubMed Web of Science ®Google Scholar
• Kovesdy CP. Management of hyperkalaemia in chronic kidney disease. Nat Rev Nephrol. 2014;10(11):653–662.
   PubMed Web of Science ®Google Scholar
• Lazich L, Bakris GL. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin Nephrol. 2014;34(3):333–339.
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Blacklock R, Wood E, et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. CJASN. 2012;7(8):1234–1241.
   PubMed Web of Science ®Google Scholar
• Jain N, Kotla S, Little BB, et al. Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol. 2012;109(10):1510–1513.
   PubMed Web of Science ®Google Scholar
• Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004;351(6):585–592.
   PubMed Web of Science ®Google Scholar
• Albert NM, Yancy C, Liang L, et al. Use of aldosterone antagonists in heart failure. JAMA. 2009;302(15):1658–1665.
   PubMed Web of Science ®Google Scholar
• Betts KA, Woolley JM, Mu F, et al. The prevalence of hyperkalemia in the United States. Curr Med Res Opin. 2018;34(6):971–978.
   PubMed Web of Science ®Google Scholar
• Fitch K, Woolley JM, Engel T, et al. The clinical and economic burden of hyperkalemia on medicare and commercial payers. Am Health Drug Benefits. 2017;10(4):202–210.
   PubMed Web of Science ®Google Scholar
• Mu F, Betts KA, Woolley JM, et al. Prevalence and economic burden of hyperkalemia in the United States medicare population. Curr Med Res Opin. 2020;36(8):1333–1341.
   PubMed Web of Science ®Google Scholar
• Betts KA, Woolley JM, Mu F, et al. Postdischarge health care costs and readmission in patients with hyperkalemia-related hospitalizations. Kidney Int Rep. 2020;5(8):1280–1290.
   PubMed Web of Science ®Google Scholar
• Betts KA, Woolley JM, Mu F, et al. The cost of hyperkalemia in the United States. Kidney Int Rep. 2017;3(2):385–393.
   PubMed Web of Science ®Google Scholar
• Pitt B, Bakris GL, Bushinsky DA, et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail. 2015;17(10):1057–1065.
   PubMed Web of Science ®Google Scholar
• Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015;372(3):211–221.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Pitt B, Weir MR, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA. 2015;314(2):151–161.
   PubMed Web of Science ®Google Scholar
• Kovesdy CP, Gosmanova EO, Woods SD, et al. Real-world management of hyperkalemia with patiromer among United States veterans. Postgrad Med. 2020;132(2):176–183.
   PubMed Web of Science ®Google Scholar
• Kovesdy CP, Gosmanova E, Woods SD, et al. Hospital and emergency department utilization in US veterans with hyperkalemia. Diabetes. 2020;69(Supplement 1):1087.
   PubMed Web of Science ®Google Scholar
• Desai NR, Rowan CG, Alvarez PJ, et al. Hyperkalemia treatment modalities: a descriptive observational study focused on medication and healthcare resource utilization. PLOS One. 2020;15(1):e0226844.
   PubMed Web of Science ®Google Scholar
• Desai NR, Rowan CG, Alvarez PJ, et al. Outpatient cost-effectiveness study of hyperkalemia management. J Cardiac Fail. 2020;26(10):S115.
   Web of Science ®Google Scholar
• Kovesdy CP, Rowan CG, Conrad A, et al. Real-world evaluation of patiromer for the treatment of hyperkalemia in hemodialysis patients. Kidney Int Rep. 2019;4(2):301–309.
   PubMed Web of Science ®Google Scholar
• Kovesdy CP, Gosmanova EO, Woods SD, et al. Emergency department visits and hospitalizations in US veterans with hyperkalemia. Am J Kidney Dis. 2019;73(5):690.
   Web of Science ®Google Scholar
• Gosmanova EO, Kovesdy CP, Woods SD, et al. Disparities in real-world utilization patterns of potassium binders in US veterans with hyperkalemia. Nephrol Nurs J. 2019;46(2):238.
   Web of Science ®Google Scholar
• Ripollone JE, Huybrechts KF, Rothman KJ, et al. Evaluating the utility of coarsened exact matching for pharmacoepidemiology using real and simulated claims data. Am J Epidemiol. 2020;189(6):613–622.
   PubMed Web of Science ®Google Scholar
• Wells AR, Hamar B, Bradley C, et al. Exploring robust methods for evaluating treatment and comparison groups in chronic care management programs. Popul Health Manag. 2013;16(1):35–45.
   PubMed Web of Science ®Google Scholar
• Iacus SM, King G, Porro G. Causal inference without balance checking: coarsened exact matching. Polit Anal. 2012;20(1):1–24.
   Web of Science ®Google Scholar
• Schneeweiss S, Rassen JA, Glynn RJ, et al. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20(4):512–522.
   PubMed Web of Science ®Google Scholar
• Moore BJ, Liang L. Medicare advantage versus the traditional medicare program: costs of inpatient stays, 2009–2017: statistical brief #262. Healthcare cost and utilization project (HCUP) statistical briefs. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020.
   Google Scholar
• Drieling RL, LaCroix AZ, Beresford SAA, et al. Validity of self-reported medication use compared with pharmacy records in a cohort of older women: findings from the women's health initiative. Am J Epidemiol. 2016;184(3):233–238.
   PubMed Web of Science ®Google Scholar
• Richardson K, Kenny RA, Peklar J, et al. Agreement between patient interview data on prescription medication use and pharmacy records in those aged older than 50 years varied by therapeutic group and reporting of indicated health conditions. J Clin Epidemiol. 2013;66(11):1308–1316.
   PubMed Web of Science ®Google Scholar
• Grymonpre R, Cheang M, Fraser M, et al. Validity of a prescription claims database to estimate medication adherence in older persons. Med Care. 2006;44(5):471–477.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Westfall AO, Allison J, et al. Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users. Pharmacoepidemiol Drug Saf. 2006;15(10):710–718.
   PubMed Web of Science ®Google Scholar
• Erickson SR, Coombs JH, Kirking DM, et al. Compliance from self-reported versus pharmacy claims data with metered-dose inhalers. Ann Pharmacother. 2001;35(9):997–1003.
   PubMed Web of Science ®Google Scholar
• Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006;43(1):78–84.
   PubMed Web of Science ®Google Scholar